scholarly journals A second KIGS communication on side effects of growth hormone therapy

1993 ◽  
Vol 39 (5) ◽  
pp. 85-88
Author(s):  
P. J. Chatlein ◽  
P. Wilton

By March 25, 1992, among the 16,604 patients included in the KIGS database who had been treated with growth hormone (GH) for at least one year, 135 had serious side effects (SE). Among the most frequent SE are relapses of craniopharyngioma (17) and other brain tumors (11). Changes in bone tissue, joints and muscles were more rarely observed. 7 patients had convulsive syndrome. More information is needed to assess the effect of GH therapy on these complications.

1987 ◽  
Vol 116 (3_Suppl) ◽  
pp. S188-S189 ◽  
Author(s):  
K.P. RODENS ◽  
S.L. KAPLAN ◽  
M.M. GRUMBACH ◽  
W.M. TELLER

PEDIATRICS ◽  
1973 ◽  
Vol 52 (4) ◽  
pp. 626-626
Author(s):  
Robert L. Rosenfield ◽  
Samuel Refetoff ◽  
Leslie J. DeGroot

Drs. Sack and DeLamater quote our paper as confirming the observation that hypothyroidism develops in growth hormone (GH)-deficient patients upon the institution of GH therapy. This statement is incorrect since no significant change in thyroid function was observed during several months of GH therapy. In fact, our data may be interpreted as indicating that some GH-deficient patients have a state of hypothyroidism undetectable by measurement of serum total and free thyroxine levels prior to the institution of GH replacement.


2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jing Wu ◽  
Fei Zhao ◽  
Yuan Zhang ◽  
Jiang Xue ◽  
Jiangying Kuang ◽  
...  

It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P<0.001) and insulin-like growth factor 1 levels increased (P<0.001). GH treatment also reduced low density lipoprotein cholesterol (P<0.001), total cholesterol (P<0.001), triglycerides (P=0.042), and alanine aminotransferase (P=0.027) when compared with the baseline. One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.


2018 ◽  
Vol 25 (1) ◽  
pp. 13-17 ◽  
Author(s):  
Maria Pankratova ◽  
Alexander Yusipovich ◽  
Maria Vorontsova ◽  
Evgenia Parshina ◽  
Svetlana Bochkareva ◽  
...  

2013 ◽  
Vol 39 (2) ◽  
pp. 74-79 ◽  
Author(s):  
Vaman Khadilkar ◽  
Veena Ekbote ◽  
Neha Kajale ◽  
Anuradha Khadilkar ◽  
Shashi Chiplonkar ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document